Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
04 2021
Historique:
revised: 08 12 2020
received: 02 06 2020
accepted: 24 12 2020
pubmed: 19 3 2021
medline: 31 7 2021
entrez: 18 3 2021
Statut: ppublish

Résumé

Blinatumomab is a BiTE

Sections du résumé

BACKGROUND
Blinatumomab is a BiTE

Identifiants

pubmed: 33734596
doi: 10.1002/cam4.3731
pmc: PMC8026950
doi:

Substances chimiques

Antibodies, Bispecific 0
Antineoplastic Agents 0
blinatumomab 4FR53SIF3A

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2601-2610

Informations de copyright

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
Cancer. 2010 Dec 15;116(24):5568-74
pubmed: 20737576
Int J Cancer. 2002 Aug 20;100(6):690-7
pubmed: 12209608
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
Lancet Oncol. 2015 Jan;16(1):57-66
pubmed: 25524800
Leukemia. 2010 Mar;24(3):521-35
pubmed: 20033054
J Clin Oncol. 2011 Jun 20;29(18):2493-8
pubmed: 21576633
J Clin Oncol. 2016 Apr 1;34(10):1104-11
pubmed: 26884582
Hematology. 2019 Dec;24(1):337-348
pubmed: 30757960
Blood. 2018 Apr 5;131(14):1522-1531
pubmed: 29358182
J Clin Oncol. 2014 Dec 20;32(36):4134-40
pubmed: 25385737
Leukemia. 2003 May;17(5):900-9
pubmed: 12750704
Cancer. 2017 Jan 1;123(2):294-302
pubmed: 27602508
Cancer. 2008 Dec 1;113(11):3186-91
pubmed: 18846563
Haematologica. 2016 Dec;101(12):1524-1533
pubmed: 27587380
Br J Haematol. 2010 Aug;150(4):389-405
pubmed: 20573154
Blood. 2016 Mar 17;127(11):1410-6
pubmed: 26755709
Best Pract Res Clin Haematol. 2017 Sep;30(3):261-274
pubmed: 29050699
Int J Cancer. 2005 May 20;115(1):98-104
pubmed: 15688411
Haematologica. 2010 Apr;95(4):589-96
pubmed: 20145276
Hematology. 2003 Aug;8(4):233-42
pubmed: 12911941

Auteurs

Max S Topp (MS)

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

Anthony S Stein (AS)

Gehr Leukemia Center, City of Hope Medical Center, Duarte, CA, USA.

Nicola Gökbuget (N)

Medizinische Klinik III (Hämatologie/Onkologie/Rheumatologie/Infektiologie, Universitätsklinikum, Frankfurt, Germany.

Heinz-August Horst (HA)

Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

Nicolas Boissel (N)

Unité d'Hématologie Adolescents et Jeunes Adultes, Hôpital Saint-Louis, Paris, France.

Giovanni Martinelli (G)

Scientific Directorate, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy.

Hagop Kantarjian (H)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Monika Brüggemann (M)

Sektion für Hämatologische Spezialdiagnostik Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

Yuqi Chen (Y)

Global Biostatistical Science, Amgen Inc, Thousand Oaks, California, USA.

Gerhard Zugmaier (G)

Global Development, Amgen Research (Munich) GmbH, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH